Moderna, Inc. (VIE:MRNA)
Austria · Delayed Price · Currency is EUR | Market Cap | 70.23B +667.7% |
| Revenue (ttm) | 1.95B -27.6% |
| Net Income | -2.76B |
| EPS | -7.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 318 |
| Open | 172.60 |
| Previous Close | 172.60 |
| Day's Range | 172.60 - 177.38 |
| 52-Week Range | 19.48 - 183.36 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
The healthcare sector stood out as one of the few bright spots in Wednesday's trading.
Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell
Moderna stock (NASDAQ: MRNA) rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking fu...
Nike, ON Semi, Moderna, and More Stocks That Explain Today's Market
Nike slumps after the retailer misses analysts' first-quarter earnings target and issues downbeat full-year guidance.
Moderna to replace Warner Bros Discovery on Nasdaq 100
Nasdaq said on Thursday that vaccine maker Moderna will replace Warner Bros. Discovery on the Nasdaq 100 index , effective October 9.
Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year
Moderna's stock has been flying high lately. That has one group of analysts saying it's time to sell.
Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter
Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.
Wednesday's First Moves: MRNA Downgrade, BA Jet Contract, JBL Earnings
Citi downgraded Moderna (MRNA) following the stock's astronomical rally in recent weeks. Boeing (BA) pens a $20 billion deal with the U.S. Navy for its next generation fighter jets.
Moderna stock falls 6% in premarket: here's why
Moderna stock MRNA fell nearly 6% in premarket trading on Wednesday after Citi downgraded the biotech company to ‘Sell' from ‘Hold', citing concerns that its recent valuation is difficult to justify. ...
Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell.
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn't enough to justify the valuation.
Citi tells investors it's time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna's share price, according to Citi's analysts.
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna CAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 / Moderna, Inc. (N...
Moderna CEO's Realistic Approach to Innovation
Moderna's share price popped in August on positive news about its therapeutic cancer vaccine to prevent melanoma from recurring. At Journal House, United Nations General Assembly yesterday, the Journa...
Moderna CEO's Surprising Comment Gives Clues About Where Drugmaker Is Going Next
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been' just a Covid vaccine company.
Moderna Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
The forum highlighted a shift from a COVID-19 focus to a broad mRNA platform spanning vaccines, oncology, rare diseases, and autoimmune therapies. Key advances include intismeran's strong phase III results, expansion into new indications, and a robust pipeline supported by proprietary manufacturing and AI-driven R&D.
Moderna will reveal the data for its mRNA cancer vaccine next month. Here's why it matters.
One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event v...
Moderna stock rises 8%: can it continue its cancer vaccine success rally?
Moderna (MRNA) stock continued to rise on Thursday as investors assessed positive late-stage results for the company's personalised mRNA cancer vaccine and a series of analyst upgrades and higher pric...
Moderna's AI-Built Cancer Vaccine Clears Phase 3 With Merck
Moderna built an artificial intelligence that reads a patient's tumor and decides what that patient's medicine should be. That approach just cleared its biggest test.
Moderna Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Positive phase III melanoma data validates the T-cell priming approach, with broad ongoing trials in lung, bladder, and renal cancers. Manufacturing is already at commercial scale, supporting global trials and future launches. The expanding vaccine portfolio and innovative mRNA technology underpin growth and margin confidence.
AI & Robotics in 2026: 16 Recent Developments for Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference,...
Moderna cancer vaccine BREAKTHROUGH drives new hope after phase 3 trial
Moderna co-founder and board chairman Noubar Afeyan discusses the phase three success of the Moderna-Merck cancer vaccine trial and explains how the vaccine targets unique mutations to help prevent me...
Beyond NVDA: New Frontiers in Space Stocks, Healthcare AI
Sydney Armani, CEO of AI Fintech World Group, discusses Nvidia (NVDA) continuing its climb after a stellar earnings report, with 2028 revenue projections soaring and its dominance in data center code ...
Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.
2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert sai...
Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets
Moderna consolidates after a dramatic breakout, with a bullish pennant forming near resistance and offering a potential signal for another powerful advance.